Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 08:59
01/13/22
01/13
08:59
01/13/22
08:59
BA

Boeing

$217.57 /

+1.54 (+0.71%)

, PBYI

Puma Biotechnology

$2.63 /

-0.11 (-4.01%)

, ADGI

Adagio Therapeutics

$5.85 /

-0.16 (-2.66%)

, DAL

Delta Air Lines

$40.58 /

-0.655 (-1.59%)

, KBH

KB Home

$42.39 /

+0.24 (+0.57%)

, TSM

TSMC

$132.28 /

+3.105 (+2.40%)

, SPCE

Virgin Galactic

$12.37 /

-0.015 (-0.12%)

, QRVO

Qorvo

$152.89 /

+1.06 (+0.70%)

, MRNA

Moderna

$222.92 /

+1.53 (+0.69%)

, CF

CF Industries

$67.87 /

-1.245 (-1.80%)

Check out this morning's…

ShowHide Related Items >><<
TSM TSMC
$132.28 /

+3.105 (+2.40%)

SPCE Virgin Galactic
$12.37 /

-0.015 (-0.12%)

QRVO Qorvo
$152.89 /

+1.06 (+0.70%)

PBYI Puma Biotechnology
$2.63 /

-0.11 (-4.01%)

MRNA Moderna
$222.92 /

+1.53 (+0.69%)

KBH KB Home
$42.39 /

+0.24 (+0.57%)

DAL Delta Air Lines
$40.58 /

-0.655 (-1.59%)

CF CF Industries
$67.87 /

-1.245 (-1.80%)

BA Boeing
$217.57 /

+1.54 (+0.71%)

ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

BA Boeing
$217.57 /

+1.54 (+0.71%)

01/12/22 Morgan Stanley
News of 737 MAX flight in China a positive for Boeing, says Morgan Stanley
01/06/22 Susquehanna
Boeing MAX order starts year off right, says Susquehanna
12/22/21 Susquehanna
China ungrounding key event for Boeing in 2022, says Susquehanna
12/20/21 BofA
Boeing price target lowered to $220 from $245 at BofA
PBYI Puma Biotechnology
$2.63 /

-0.11 (-4.01%)

09/28/21
Fly Intel: Top five analyst upgrades
09/28/21 Citi
Puma Biotechnology upgraded to Buy after 40% selloff at Citi
09/27/21 Citi
Puma Biotechnology upgraded to Buy from Neutral at Citi
ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

01/13/22 Morgan Stanley
Adagio's ADG20 timeline and approval path still uncertain, says Morgan Stanley
01/06/22 Morgan Stanley
Adagio Therapeutics downgraded to Underweight from Equal Weight at Morgan Stanley
12/22/21
Fly Intel: Top five analyst downgrades
12/22/21 Jefferies
Jefferies downgrades Adagio on uncertainty over COVID antibody
DAL Delta Air Lines
$40.58 /

-0.655 (-1.59%)

01/13/22 Susquehanna
Delta Air Lines upgraded to Positive with $50 price target at Susquehanna
01/13/22 Susquehanna
Delta Air Lines upgraded to Positive from Neutral at Susquehanna
01/07/22 BofA
BofA upgrades Delta to Buy, thinks poor sentiment could set up bounce
01/07/22 BofA
Delta Air Lines upgraded to Buy from Neutral at BofA
KBH KB Home
$42.39 /

+0.24 (+0.57%)

01/13/22 Wedbush
KB Home price target raised to $73 from $60 at Wedbush
01/13/22 RBC Capital
KB Home price target raised to $55 from $46 at RBC Capital
01/10/22 RBC Capital
KB Home upgraded to Outperform from Sector Perform at RBC Capital
12/15/21 Barclays
KB Home price target raised to $57 from $56 at Barclays
TSM TSMC
$132.28 /

+3.105 (+2.40%)

01/12/22 DZ Bank
TSMC initiated with a Buy at DZ Bank
01/11/22 Cowen
TSMC price target raised to $125 from $120 at Cowen
01/11/22 New Street
New Street sees now as 'ideal timing to invest' in TSMC
11/01/21 Northland
Intel upgraded to Market Perform on new CEO's plan at Northland
SPCE Virgin Galactic
$12.37 /

-0.015 (-0.12%)

10/19/21 Morgan Stanley
Virgin Galactic price target lowered to $17 from $25 at Morgan Stanley
10/18/21 UBS
Virgin Galactic downgraded to Sell from Neutral at UBS
10/18/21 UBS
Virgin Galactic downgraded to Sell from Neutral at UBS
10/15/21 Canaccord
Virgin Galactic flight delay not significant to long-term plans, says Canaccord
QRVO Qorvo
$152.89 /

+1.06 (+0.70%)

01/13/22 Oppenheimer
Qorvo downgraded to Perform from Outperform at Oppenheimer
12/16/21 Piper Sandler
Piper 'skeptical' of Apple bringing wireless chip development in house
12/16/21 KeyBanc
Survey indicates iPhone 13 supply remains heavily constrained, says KeyBanc
11/15/21 KeyBanc
Demand remains strong, shortages limit iPhone 13 sell-through, says KeyBanc
MRNA Moderna
$222.92 /

+1.53 (+0.69%)

01/06/22 Argus
Moderna price target lowered to $350 from $420 at Argus
01/05/22 Piper Sandler
Piper keeps $348 target on Moderna after Epstein-Barr vaccine trial starts
12/20/21 Piper Sandler
Piper keeps Overweight rating, $348 price target on Moderna after omicron data
12/16/21 Piper Sandler
Arcturus data shows 'legit player' in COVID vaccines, says Piper Sandler
CF CF Industries
$67.87 /

-1.245 (-1.80%)

01/13/22 Berenberg
CF Industries downgraded to Hold from Buy at Berenberg
01/11/22 Citi
CF Industries price target raised to $86 from $69 at Citi
12/17/21
Fly Intel: Top five analyst initiations
12/17/21 Piper Sandler
CF Industries initiated with Overweight, $78 target at Piper Sandler
TSM TSMC
$132.28 /

+3.105 (+2.40%)

SPCE Virgin Galactic
$12.37 /

-0.015 (-0.12%)

QRVO Qorvo
$152.89 /

+1.06 (+0.70%)

PBYI Puma Biotechnology
$2.63 /

-0.11 (-4.01%)

MRNA Moderna
$222.92 /

+1.53 (+0.69%)

KBH KB Home
$42.39 /

+0.24 (+0.57%)

DAL Delta Air Lines
$40.58 /

-0.655 (-1.59%)

CF CF Industries
$67.87 /

-1.245 (-1.80%)

BA Boeing
$217.57 /

+1.54 (+0.71%)

ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

  • 06
    Aug
TSM TSMC
$132.28 /

+3.105 (+2.40%)

SPCE Virgin Galactic
$12.37 /

-0.015 (-0.12%)

QRVO Qorvo
$152.89 /

+1.06 (+0.70%)

MRNA Moderna
$222.92 /

+1.53 (+0.69%)

KBH KB Home
$42.39 /

+0.24 (+0.57%)

DAL Delta Air Lines
$40.58 /

-0.655 (-1.59%)

BA Boeing
$217.57 /

+1.54 (+0.71%)

TSM TSMC
$132.28 /

+3.105 (+2.40%)

SPCE Virgin Galactic
$12.37 /

-0.015 (-0.12%)

QRVO Qorvo
$152.89 /

+1.06 (+0.70%)

PBYI Puma Biotechnology
$2.63 /

-0.11 (-4.01%)

MRNA Moderna
$222.92 /

+1.53 (+0.69%)

KBH KB Home
$42.39 /

+0.24 (+0.57%)

DAL Delta Air Lines
$40.58 /

-0.655 (-1.59%)

CF CF Industries
$67.87 /

-1.245 (-1.80%)

BA Boeing
$217.57 /

+1.54 (+0.71%)

ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

TSM TSMC
$132.28 /

+3.105 (+2.40%)

SPCE Virgin Galactic
$12.37 /

-0.015 (-0.12%)

MRNA Moderna
$222.92 /

+1.53 (+0.69%)

KBH KB Home
$42.39 /

+0.24 (+0.57%)

DAL Delta Air Lines
$40.58 /

-0.655 (-1.59%)

CF CF Industries
$67.87 /

-1.245 (-1.80%)

BA Boeing
$217.57 /

+1.54 (+0.71%)

ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

Recommendations
Adagio's ADG20 timeline and approval path still uncertain, says Morgan Stanley » 07:04
01/13/22
01/13
07:04
01/13/22
07:04
ADGI

Adagio Therapeutics

$5.85 /

-0.16 (-2.66%)

After Adagio…

After Adagio Therapeutics' management provided an update on ADG20 neutralization activity with recently published data and highlighted data that indicate ADG20 retains some neutralization activity against omicron, Morgan Stanley analyst Matthew Harrison pointed out that management noted that it's unclear whether the FDA would allow the company to include higher dose arm(s) without conducting a Phase 1 trial and added that he thinks it is unclear when the FDA would be able to provide an update on the proposed protocol change, making the timeline and approval pathway uncertain. While the ADG20 update is likely to be perceived positively, he believes Adagio's COVID opportunity remains uncertain and Harrison maintains an Underweight rating and $6 price target on the shares, which are up $1.00, or 17%, to $6.83 in pre-market trading.

ShowHide Related Items >><<
ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

01/06/22 Morgan Stanley
Adagio Therapeutics downgraded to Underweight from Equal Weight at Morgan Stanley
12/22/21
Fly Intel: Top five analyst downgrades
12/22/21 Jefferies
Jefferies downgrades Adagio on uncertainty over COVID antibody
12/22/21 Jefferies
Adagio Therapeutics downgraded to Hold from Buy at Jefferies
ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

  • 06
    Aug
ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

Hot Stocks
Adagio Therapeutics spikes higher after report on ADG20 against Omicron » 17:48
01/12/22
01/12
17:48
01/12/22
17:48
ADGI

Adagio Therapeutics

$5.85 /

-0.16 (-2.66%)

Shares of Adagio…

Shares of Adagio Therapeutics are up approximately 23% or $1.33 per share to approximately $7.22 in after-hours trading on Wednesday after reporting recent findings reported in three separate publications that show ADG20, its lead monoclonal antibody, mAb, has neutralization activity against the Omicron variant of SARS-CoV-2, and outlined initiatives to address current and future SARS-CoV-2 variants of concern. Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for both the prevention and treatment of COVID-19. Adagio is engaging with the U.S. Food and Drug Administration, FDA, regarding potential protocol updates to its global Phase 2/3 clinical trials, including an increased dose of ADG20 for the potential prevention and treatment of COVID-19 resulting from the Omicron variant.

ShowHide Related Items >><<
ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

01/06/22 Morgan Stanley
Adagio Therapeutics downgraded to Underweight from Equal Weight at Morgan Stanley
12/22/21
Fly Intel: Top five analyst downgrades
12/22/21 Jefferies
Jefferies downgrades Adagio on uncertainty over COVID antibody
12/22/21 Jefferies
Adagio Therapeutics downgraded to Hold from Buy at Jefferies
ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

  • 06
    Aug
ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

Hot Stocks
Adagio summarizes neutralization activity of its mAb ADG20 against Omicron » 17:37
01/12/22
01/12
17:37
01/12/22
17:37
ADGI

Adagio Therapeutics

$5.85 /

-0.16 (-2.66%)

Adagio Therapeutics…

Adagio Therapeutics summarized recent findings reported in three separate publications that show ADG20, its lead monoclonal antibody, mAb, has neutralization activity against the Omicron variant of SARS-CoV-2, and outlined initiatives to address current and future SARS-CoV-2 variants of concern. Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for both the prevention and treatment of COVID-19. Adagio is engaging with the U.S. Food and Drug Administration, FDA, regarding potential protocol updates to its global Phase 2/3 clinical trials, including an increased dose of ADG20 for the potential prevention and treatment of COVID-19 resulting from the Omicron variant. Recently published in vitro studies examined the neutralization potencies of large panels of mAbs against the Omicron variant in both authentic and pseudovirus assays. Findings across all three studies show that among mAbs in late-stage clinical development or with Emergency Use Authorization, EUA, ADG20 is one of only a few mAbs that demonstrated neutralizing activity against Omicron. Across two distinct authentic neutralization assays against Omicron, the data show that ADG20 had an IC50, a measurement of neutralization potency, of approximately 0.4 to 1.1 microgram/mL, which is comparable with the two other active mAbs, sotrovimab and AZD7742...In addition to its clinical trial updates, Adagio is pursuing multiple strategies to address both Omicron and potential future variants that may emerge.

ShowHide Related Items >><<
ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

01/06/22 Morgan Stanley
Adagio Therapeutics downgraded to Underweight from Equal Weight at Morgan Stanley
12/22/21
Fly Intel: Top five analyst downgrades
12/22/21 Jefferies
Jefferies downgrades Adagio on uncertainty over COVID antibody
12/22/21 Jefferies
Adagio Therapeutics downgraded to Hold from Buy at Jefferies
ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

  • 06
    Aug
ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

ADGI Adagio Therapeutics
$5.85 /

-0.16 (-2.66%)

Downgrade
Adagio Therapeutics downgraded to Underweight from Equal Weight at Morgan Stanley » 08:13
01/06/22
01/06
08:13
01/06/22
08:13
ADGI

Adagio Therapeutics

$6.50 /

-0.72 (-9.97%)

Morgan Stanley analyst…

Morgan Stanley analyst Matthew Harrison downgraded Adagio Therapeutics to Underweight from Equal Weight with a price target of $6, down from $11. He believes its "major product," mAB ADG-20/10, has missed the critical window to achieve a major bolus of COVID sales and even if it is approved he does not expect major government contracts or stockpiling, Harrison tells investors. Meanwhile, the company's non-COVID pipeline is still in the pre-clinical stage and "too early to place significant value" on, Harrison said.

ShowHide Related Items >><<
ADGI Adagio Therapeutics
$6.50 /

-0.72 (-9.97%)

ADGI Adagio Therapeutics
$6.50 /

-0.72 (-9.97%)

12/22/21
Fly Intel: Top five analyst downgrades
12/22/21 Jefferies
Jefferies downgrades Adagio on uncertainty over COVID antibody
12/22/21 Jefferies
Adagio Therapeutics downgraded to Hold from Buy at Jefferies
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
ADGI Adagio Therapeutics
$6.50 /

-0.72 (-9.97%)

  • 06
    Aug
ADGI Adagio Therapeutics
$6.50 /

-0.72 (-9.97%)

ADGI Adagio Therapeutics
$6.50 /

-0.72 (-9.97%)

Options
Four new option listings and one option delisting on December 27th » 08:30
12/27/21
12/27
08:30
12/27/21
08:30
ADGI

Adagio Therapeutics

$8.64 /

-0.27 (-3.03%)

, PECO

Phillips Edison

$31.16 /

-0.02 (-0.06%)

, PTPI

Petros Pharmaceuticals

$3.47 /

+0.16 (+4.83%)

, FATH

Fathom

$10.50 /

+ (+0.00%)

, ATMR

Altimar Acquisition Corp. II

$10.50 /

+0.99 (+10.41%)

New option listings for…

New option listings for December 27th include Adagio Therapeutics Inc (ADGI), Phillips Edison and Company Inc (PECO), Petros Pharmaceuticals (PTPI), and FATH Stock (FATH). Option delistings effective December 27th include Altimar Acquisition Corp II (ATMR).

ShowHide Related Items >><<
PTPI Petros Pharmaceuticals
$3.47 /

+0.16 (+4.83%)

PECO Phillips Edison
$31.16 /

-0.02 (-0.06%)

ATMR Altimar Acquisition Corp. II
$10.50 /

+0.99 (+10.41%)

ADGI Adagio Therapeutics
$8.64 /

-0.27 (-3.03%)

ADGI Adagio Therapeutics
$8.64 /

-0.27 (-3.03%)

12/22/21
Fly Intel: Top five analyst downgrades
12/22/21 Jefferies
Jefferies downgrades Adagio on uncertainty over COVID antibody
12/22/21 Jefferies
Adagio Therapeutics downgraded to Hold from Buy at Jefferies
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
PECO Phillips Edison
$31.16 /

-0.02 (-0.06%)

12/14/21 Wells Fargo
Wells Fargo downgrades Phillips Edison to Equal Weight after outperformance
12/14/21 Wells Fargo
Phillips Edison downgraded to Equal Weight from Overweight at Wells Fargo
08/09/21
Fly Intel: Top five analyst initiations
08/09/21 JPMorgan
JPMorgan starts Phillips Edison at Neutral, but likes 'acquisition potential'
PTPI Petros Pharmaceuticals
$3.47 /

+0.16 (+4.83%)

FATH Fathom
$10.50 /

+ (+0.00%)

ATMR Altimar Acquisition Corp. II
$10.50 /

+0.99 (+10.41%)

10/06/21
Fly Intel: Top five analyst initiations
10/06/21 Lake Street
Altimar Acquisition Corp. II initiated with a Buy at Lake Street
PECO Phillips Edison
$31.16 /

-0.02 (-0.06%)

ADGI Adagio Therapeutics
$8.64 /

-0.27 (-3.03%)

  • 06
    Aug
  • 15
    Jul
PTPI Petros Pharmaceuticals
$3.47 /

+0.16 (+4.83%)

PECO Phillips Edison
$31.16 /

-0.02 (-0.06%)

ATMR Altimar Acquisition Corp. II
$10.50 /

+0.99 (+10.41%)

ADGI Adagio Therapeutics
$8.64 /

-0.27 (-3.03%)

PTPI Petros Pharmaceuticals
$3.47 /

+0.16 (+4.83%)

ATMR Altimar Acquisition Corp. II
$10.50 /

+0.99 (+10.41%)

Over a month ago
Downgrade
Fly Intel: Top five analyst downgrades » 10:00
12/22/21
12/22
10:00
12/22/21
10:00
ADGI

Adagio Therapeutics

$8.70 /

-1.58 (-15.37%)

, AGCO

Agco

$113.75 /

-0.36 (-0.32%)

, CGC

Canopy Growth

$9.46 /

-0.185 (-1.92%)

, ALLK

Allakos

$10.31 /

-73.87 (-87.75%)

, ALXO

ALX Oncology

$21.00 /

-1.89 (-8.26%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Adagio Therapeutics (ADGI) downgraded to Hold from Buy at Jefferies with analyst Michael Yee saying the company's lead drug ADG20 is currently in Phase III for treatment and prevention of COVID-19 and hesees uncertainty around the next steps and development plan saying the antibody has reduced neutralization against the omicron variant. 2. Agco (AGCO) downgraded to Market Perform from Outperform at Bernstein with analyst Chad Dillard saying 90% of Agco's end markets are at their peak, with North America small and large ag and Europe exiting 2022 above historical peaks. 3. Canopy Growth (CGC) downgraded to Underperform from Neutral at BofA with analyst Lisa Lewandowski noting that while she sees long-term potential for the legal cannabis industry driven by U.S. Federal legalization and changing attitudes toward cannabis consumption, the company is faced with challenges from execution issues and a tough Canadian operating environment. 4. Allakos (ALLK) downgraded to Hold from Buy at Jefferies, and downgraded to Market Perform from Outperform at Cowen, William Blair and SVB Leerink. 5. ALX Oncology (ALXO) downgraded to Hold from Buy at Jefferies with analyst Michael Yee saying investors were excited for ALXO's CD47 in myelodysplastic syndromes but it failed to meet expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
CGC Canopy Growth
$9.46 /

-0.185 (-1.92%)

ALXO ALX Oncology
$21.00 /

-1.89 (-8.26%)

ALLK Allakos
$10.31 /

-73.87 (-87.75%)

AGCO Agco
$113.75 /

-0.36 (-0.32%)

ADGI Adagio Therapeutics
$8.70 /

-1.58 (-15.37%)

ADGI Adagio Therapeutics
$8.70 /

-1.58 (-15.37%)

12/22/21 Jefferies
Jefferies downgrades Adagio on uncertainty over COVID antibody
12/22/21 Jefferies
Adagio Therapeutics downgraded to Hold from Buy at Jefferies
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
12/16/21 Jefferies
Pre-prints suggest Adagio's ADG20 may have use against omicron, says Jefferies
AGCO Agco
$113.75 /

-0.36 (-0.32%)

12/22/21 Bernstein
Agco downgraded to Market Perform from Outperform at Bernstein
12/22/21 Bernstein
Agco downgraded to Market Perform from Outperform at Bernstein
12/17/21 Barclays
Agco price target lowered to $123 from $140 at Barclays
12/09/21 Deutsche Bank
Agco downgraded on peak demand concerns at Deutsche Bank
CGC Canopy Growth
$9.46 /

-0.185 (-1.92%)

12/22/21 BofA
Canopy Growth downgraded to Underperform from Neutral at BofA
12/22/21 BofA
Canopy Growth downgraded to Underperform from Neutral at BofA
12/20/21 Piper Sandler
Canopy Growth downgraded to Underweight from Neutral at Piper Sandler
12/08/21 Cantor Fitzgerald
TerrAscend price target raised to $7.65 from $6.70 at Cantor Fitzgerald
ALLK Allakos
$10.31 /

-73.87 (-87.75%)

12/22/21 Jefferies
Allakos downgraded to Hold from Buy at Jefferies
12/22/21 William Blair
Allakos downgraded to Market Perform on trial failures at William Blair
12/22/21 Cowen
Allakos downgraded to Market Perform from Outperform at Cowen
12/22/21 Morgan Stanley
Allakos' 'disappointing' data increase EGID uncertainty, says Morgan Stanley
ALXO ALX Oncology
$21.00 /

-1.89 (-8.26%)

12/22/21 Jefferies
ALX Oncology downgraded to Hold on MDS uncertainty at Jefferies
12/22/21 Jefferies
ALX Oncology downgraded to Hold from Buy at Jefferies
12/14/21 Credit Suisse
ALX Oncology price target lowered to $53 from $83 at Credit Suisse
12/13/21 Stifel
ALX evorpacept data might not yet counter recent negative sentiment, says Stifel
CGC Canopy Growth
$9.46 /

-0.185 (-1.92%)

ALLK Allakos
$10.31 /

-73.87 (-87.75%)

AGCO Agco
$113.75 /

-0.36 (-0.32%)

ADGI Adagio Therapeutics
$8.70 /

-1.58 (-15.37%)

  • 06
    Aug
  • 13
    Jan
CGC Canopy Growth
$9.46 /

-0.185 (-1.92%)

CGC Canopy Growth
$9.46 /

-0.185 (-1.92%)

ALXO ALX Oncology
$21.00 /

-1.89 (-8.26%)

ALLK Allakos
$10.31 /

-73.87 (-87.75%)

ADGI Adagio Therapeutics
$8.70 /

-1.58 (-15.37%)

CGC Canopy Growth
$9.46 /

-0.185 (-1.92%)

Downgrade
Jefferies downgrades Adagio on uncertainty over COVID antibody » 05:26
12/22/21
12/22
05:26
12/22/21
05:26
ADGI

Adagio Therapeutics

$10.28 /

+0.125 (+1.23%)

Jefferies analyst Michael…

Jefferies analyst Michael Yee downgraded Adagio Therapeutics to Hold from Buy with a price target of $10, down from $46. The company's lead drug ADG20 is currently in Phase III for treatment and prevention of COVID-19. The analyst sees uncertainty around the next steps and development plan saying the antibody has reduced neutralization against the omicron variant. The issue is "it will take a lot of time to get more answers" and the Phase III timeline may be delayed due to shifting into new countries and to avoid omicron, Yee tells investors in a research note. Adagio shares were "very interesting near cash levels around $5 but has since doubled back up to $10 and uncertainty abounds," contends the analyst.

ShowHide Related Items >><<
ADGI Adagio Therapeutics
$10.28 /

+0.125 (+1.23%)

ADGI Adagio Therapeutics
$10.28 /

+0.125 (+1.23%)

12/22/21 Jefferies
Adagio Therapeutics downgraded to Hold from Buy at Jefferies
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
12/16/21 Jefferies
Pre-prints suggest Adagio's ADG20 may have use against omicron, says Jefferies
12/15/21 Guggenheim
Adagio Therapeutics downgraded to Neutral from Buy at Guggenheim
ADGI Adagio Therapeutics
$10.28 /

+0.125 (+1.23%)

  • 06
    Aug
ADGI Adagio Therapeutics
$10.28 /

+0.125 (+1.23%)

Downgrade
Adagio Therapeutics downgraded to Hold from Buy at Jefferies » 04:46
12/22/21
12/22
04:46
12/22/21
04:46
ADGI

Adagio Therapeutics

$10.28 /

+0.125 (+1.23%)

Jefferies analyst Michael…

Jefferies analyst Michael Yee downgraded Adagio Therapeutics to Hold from Buy with a price target of $10, down from $46.

ShowHide Related Items >><<
ADGI Adagio Therapeutics
$10.28 /

+0.125 (+1.23%)

ADGI Adagio Therapeutics
$10.28 /

+0.125 (+1.23%)

12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
12/16/21 Jefferies
Pre-prints suggest Adagio's ADG20 may have use against omicron, says Jefferies
12/15/21 Guggenheim
Adagio Therapeutics downgraded to Neutral from Buy at Guggenheim
12/15/21 Stifel
Stifel downgrades Adagio Therapeutics, cuts target to $9 from $50
ADGI Adagio Therapeutics
$10.28 /

+0.125 (+1.23%)

  • 06
    Aug
ADGI Adagio Therapeutics
$10.28 /

+0.125 (+1.23%)

Recommendations
Adagio story 'even more complicated' after preprints on ADG20, says Stifel » 13:06
12/16/21
12/16
13:06
12/16/21
13:06
ADGI

Adagio Therapeutics

$13.78 /

+7.42 (+116.67%)

, VIR

Vir Biotechnology

$56.03 /

+4.46 (+8.65%)

, GSK

GlaxoSmithKline

$43.76 /

+0.08 (+0.18%)

, AZN

AstraZeneca

$56.66 /

+0.93 (+1.67%)

Stifel analyst Stephen…

Stifel analyst Stephen Willey said the publication within the last 12 or so hours of two preprint manuscripts including independently generated lab data that suggest a lower "omicron-induced hit" to ADG20 neutralization potency has generated significant volatility in Adagio Therapeutics (ADGI) shares and may have made the story "even more complicated." The top-line preclinical data generated in two independent and well-regarded laboratories, who also evaluated GlaxoSmithKline (GSK) and Vir Biotechnology's (VIR) sotrovimab and AstraZeneca's (AZN) Evusheld, suggest the drop in neutralization potency of ADG20 against the omicron variant may be less than the greater than 300 times reduction in neutralization potency previously advertised by the company, but Willey views it as "incomprehensible to believe" that the company's management "would have issued a press release earlier this week that destroyed billions of dollars in value without having more definitive data in hand." The analyst, who said the company suggested to him that they are actively reviewing the new data, has a Hold rating and $9 price target on Adagio shares.

ShowHide Related Items >><<
VIR Vir Biotechnology
$56.03 /

+4.46 (+8.65%)

GSK GlaxoSmithKline
$43.76 /

+0.08 (+0.18%)

AZN AstraZeneca
$56.66 /

+0.93 (+1.67%)

ADGI Adagio Therapeutics
$13.78 /

+7.42 (+116.67%)

ADGI Adagio Therapeutics
$13.78 /

+7.42 (+116.67%)

12/16/21 Jefferies
Pre-prints suggest Adagio's ADG20 may have use against omicron, says Jefferies
12/15/21 Guggenheim
Adagio Therapeutics downgraded to Neutral from Buy at Guggenheim
12/15/21 Stifel
Stifel downgrades Adagio Therapeutics, cuts target to $9 from $50
12/14/21 Stifel
Adagio Therapeutics downgraded to Hold from Buy at Stifel
VIR Vir Biotechnology
$56.03 /

+4.46 (+8.65%)

11/30/21 H.C. Wainwright
Vir Biotechnology price target raised to $200 from $135 at H.C. Wainwright
11/17/21 Baird
Baird ups Vir Biotechnology target to $36 on new U.S. contract for Sotrovimab
10/25/21
Fly Intel: Top five analyst upgrades
GSK GlaxoSmithKline
$43.76 /

+0.08 (+0.18%)

11/24/21 Berenberg
GlaxoSmithKline price target raised to 1,630 GBp from 1,540 GBp at Berenberg
11/08/21 UBS
GlaxoSmithKline price target raised to 1,500 GBp from 1,460 GBp at UBS
AZN AstraZeneca
$56.66 /

+0.93 (+1.67%)

12/12/21 Piper Sandler
Schrodinger MALT1 preclinical data supports IND filing in 1H22, says Piper
12/07/21 Jefferies
AstraZeneca downgraded to Hold from Buy at Jefferies
12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
11/29/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
VIR Vir Biotechnology
$56.03 /

+4.46 (+8.65%)

GSK GlaxoSmithKline
$43.76 /

+0.08 (+0.18%)

AZN AstraZeneca
$56.66 /

+0.93 (+1.67%)

ADGI Adagio Therapeutics
$13.78 /

+7.42 (+116.67%)

  • 06
    Aug
VIR Vir Biotechnology
$56.03 /

+4.46 (+8.65%)

GSK GlaxoSmithKline
$43.76 /

+0.08 (+0.18%)

AZN AstraZeneca
$56.66 /

+0.93 (+1.67%)

VIR Vir Biotechnology
$56.03 /

+4.46 (+8.65%)

GSK GlaxoSmithKline
$43.76 /

+0.08 (+0.18%)

AZN AstraZeneca
$56.66 /

+0.93 (+1.67%)

ADGI Adagio Therapeutics
$13.78 /

+7.42 (+116.67%)

GSK GlaxoSmithKline
$43.76 /

+0.08 (+0.18%)

AZN AstraZeneca
$56.66 /

+0.93 (+1.67%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.